The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor-Reference-Cited by-同舟云学术

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

Published:2020-04-06 Issue:10 Volume:51 Page:948-957
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Alric Hadrien¹^ORCID,Amiot Aurélien²,Kirchgesner Julien³,Tréton Xavier⁴^ORCID,Allez Matthieu⁵,Bouhnik Yoram⁴,Beaugerie Laurent³,Carbonnel Franck¹,Meyer Antoine¹^ORCID

Affiliation:

1. Assistance Publique-Hôpitaux de Paris; Hôpital Bicêtre; Université Paris Saclay; Le Kremlin Bicêtre France

2. Assitance-Publique-Hôpitaux de Paris; Hôpitaux Universitaires Henri Mondor; Université Paris Est Créteil; Créteil France

3. Assistance Publique-Hôpitaux de Paris; Hôpital Saint-Antoine; Sorbonne Université; Paris France

4. Assistance Publique-Hôpitaux de Paris; Hôpital Beaujon; Université de Paris; Clichy France

5. Assistance Publique-Hôpitaux de Paris; Hôpital Saint-Louis; Université de Paris; Paris France

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15706/fullpdf

Reference43 articles.

1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

2. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study;Kugathasan;Lancet,2017

3. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014;Kirchgesner;Aliment Pharmacol Ther,2017

4. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management;Ding;Aliment Pharmacol Ther,2016

5. Loss of response and need for adalimumab dose intensification in Crohnʼs disease: a systematic review;Billioud;Am J Gastroenterol,2011

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study;BMC Gastroenterology;2024-09-11

2. Short term effectiveness of ustekinumab versus vedolizumab in Crohn’s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis;Saudi Journal of Gastroenterology;2024-08-19

3. Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumab;Current Medical Research and Opinion;2024-08-13

4. How comparative studies can inform treatment decisions for Crohn’s disease;Expert Opinion on Biological Therapy;2024-08-12

5. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08